This article shows that unimolecular GLP1/glucagon co-agonism corrects obesity in mice
In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]
This product is not intended for direct human or veterinary administration
[1] [2] Some patients report reduced symptoms within weeks of starting treatment, whilst others may require several months of consistent supplementation before noticing significant improvement
If you are pregnant or think you may be pregnant, we recommend consulting with your licensed healthcare provider before receiving IV therapy
TelewellnessMD Jul 31, 2026 Peptide Therapy Peptide Therapies in Modern Medicine: Uses, Research and Safety Considerations Learn how peptide therapies are used in modern medicine, the conditions they may help support, current areas of research and what to know before